Brainstorm Cell Therapeutics (BCLI) Misses Q4 EPS by 3c
Get Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Oxford Industries (OXM) Reports In-Line Q4 EPS, provides guidance
- Volcon (VLCN) Reports 2023 Operational and Financial Results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!